AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Status:
Recruiting
Trial end date:
2027-02-04
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose
optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486
monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies.
The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose
optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)